Cassava Sciences, Inc. (SAVA) Class Action Update: Kessler Topaz Meltzer & Check
Kessler Topaz Meltzer & Check, LLP has recently filed a securities class action lawsuit against Cassava Sciences, Inc. This legal action stems from allegations of misleading statements and omissions that have affected the company’s stock price.
Investors who purchased Cassava Sciences, Inc. securities between February 2, 2021, and August 24, 2021, are encouraged to participate in the lawsuit. The lawsuit claims that the company failed to disclose critical information about its drug simufilam, which is being developed for the treatment of Alzheimer’s disease.
If you’re a shareholder affected by these allegations, it’s important to stay informed about the developments of this case. By understanding your rights and potential options, you can make informed decisions about your investments.
This lawsuit serves as a reminder of the importance of transparency and accurate information when it comes to investing in securities. As an investor, it’s crucial to conduct thorough research and due diligence before making any investment decisions.
We will continue to monitor this situation and provide updates as more information becomes available. Stay tuned for more news and insights on finance and securities-related matters.
